Antihypertensive and In Silico Docking Studies OF Phytoconstituents Isolated from Syzygium Alternifolium Bark

Aim of the Study: Pharmacological examination was done for methanolic extract Syzygium alternifolium bark (MESA) for its antihypertensive activity, Angiotensin converting enzyme (ACE) inhibition by in vitro and in vivo studies, antioxidant activity via radical scavenging activity.

Methods: Albino Wistar rats were allowed to treat with dexamethasone (30 μg/kg/day s.c) or saline for about 14 days. Methanolic extract of Syzygium alternifolium (300 mg/kg, b.w., p.o.) is administered from day 8 to 14 day of study to the treatment group. Chronic fructose treatment in rats showed to increase blood pressure in relationship with insulin blockade. MESA (300 mg/kg b.w, p.o) was capable of preventing the origin of hypertension by diminishing the raised blood levels i.e., blood pressure.

Results and Discussion: The decrease in the blood pressure is accredited to the restraint of ACE. The preliminary phytochemical examination suggests that the MESA has alkaloids, flavonoids, glycosides, steroids, sugars, proteins and tannins. MESA exhibited 1, 1-diphenyl-2-picrylhydrazyl interrupting radical chain reactions with IC50 value of 12.34 µg/ml just as superoxide radical scavenging ability with IC50 value of 21 µg/ml. MESA showed antihypertensive activity by limiting angiotensin converting enzyme and interrupted free radical reactions i.e., antioxidant property. These findings reveal the existence of probable active constituents of MESA. Understanding the molecular method of activity of natural product is a vital stage for creating drugs from them. The docking studies of the number of compounds were performed using mCule software. The constituents have good binding ability with ACE 1 inhibitor, Calcium channel blocker, and Renin inhibitor proteins and Ramachandran plot is analyzed.

Conclusion: The compounds from Syzygium alternifolium bark have shown antihypertensive activity when compared with standard drug Amlodipine.